[Top] [All Lists]

AFRO-NETS> GlaxoSmithKline and WHO sign agreement

GlaxoSmithKline and WHO sign agreement

Press Release WHO/10 2 March 2001  


Source: International Public HealthWatch

GlaxoSmithKline and the World Health Organization (WHO) today an-
nounce that they have signed an agreement for the development of a 
new treatment for malaria called LAPDAP. 

LAPDAP, a product that combines two existing anti-malarial compounds 
chlorproguanil and dapsone, is a potential life-saving medicine. The 
aim of the agreement is to develop LAPDAP as an effective oral treat-
ment for uncomplicated malaria, primarily for use in Sub-Saharan Af-
rica, but also in other regions of the world where this may be appro-
priate. To date, clinical trials in Sub-Saharan Africa have demon-
strated that LAPDAP is effective in the treatment of uncomplicated 
malaria including malaria resistant to other standard first line 
therapies such as chloroquine and sulphadoxine/pyrimethamine (SP). 

LAPDAP will be made available at a preferential price for public 
health programmes. The medicine is already entering its final phase 
of development and could be available in some African countries as 
early as next year. 

Both partners have contributed towards the costs of product develop-
ment and have set up a joint team to oversee the development of the 
product. Other important supporters of this initiative include the UK 
Department for International Development (DfID) and the University of 
Liverpool, UK. 

"GlaxoSmithKline firmly believes that the complex issues associated 
with meeting the healthcare needs of developing countries will only 
be resolved through collaborative effort," said Jean-Pierre Garnier, 
Chief Executive Officer, GlaxoSmithKline. 

"The LAPDAP programme further demonstrates this new company's deter-
mination to play its part in improving healthcare world-wide and in 
finding innovative and practical ways of providing much needed new 
medicines to people in developing countries." 

Dr Gro Harlem Brundtland, Director General of the World Health Or-
ganization said: "Drug resistance means that large populations in 
many parts of the world are without protection from malaria. LAPDAP 
will be an important help in reducing the burden of malaria among 
those living in Sub-Saharan Africa and elsewhere. This agreement 
shows that public-private partnerships can achieve important practi-
cal results. It is an important collaboration not only because it 
will bring a new drug to the market, but also because it includes a 
price structure that aims at making the drug affordable for those who 
need it." 

WHO, by means of its UNDP/World Bank/WHO Special Programme for Re-
search and Training in Tropical Diseases (TDR), is arranging and pro-
viding considerable financial support for clinical trials of LAPDAP. 
In addition, WHO is making available its technical expertise, espe-
cially in the area of malaria clinical trials, to the development 
team. TDR's expertise and the knowledge and experience of the WHO-led 
"Roll Back Malaria" partnership will also be available as the pro-
gramme proceeds beyond regulatory approval. 

GlaxoSmithKline will be responsible for product registrations and 
manufacture of LAPDAP. The company will also commercialise the prod-
uct in the private sector according to standard local market prac-

The UK Department for International Development (DfID) provided fund-
ing to advance the project while the University of Liverpool, UK, de-
vised the concept of LAPDAP in the early 1990s, and have continued to 
be major contributors to the programme. The Product Development Team 
is chaired by Professor Peter Winstanley of The University of Liver-

The partnership intends to extend their collaboration to develop 
LAPDAP in combination with an artemisinin derivative, in order to ex-
tend further the useful life of the new medication. 

Malaria is a serious, sometimes fatal, disease. At least 300 million 
clinical cases occur world-wide every year, 90 percent of which are 
in Africa. Every day close to 3000 people, mostly children under 
five, die as a result of this disease. 

Reprinted under the fair use doctrine of international copyright law:


Eberhard Wenzel MA PhD
International Public HealthWatch
Griffith University
School of Public Health
Meadowbrook, Qld. 4131, Australia
Tel: +61-7-3382-1026
Fax: +61-7-3382-1034
Mobile: +61-419-020-150
International Public HealthWatch:

Send mail for the `AFRO-NETS' conference to `'.
Mail administrative requests to `'.
For additional assistance, send mail to:  `'.

<Prev in Thread] Current Thread [Next in Thread>
  • AFRO-NETS> GlaxoSmithKline and WHO sign agreement, Claudio Schuftan <=